RASSF1A and RASSF1C in Pancreatic Endocrine Tumors
Author Information
Author(s): Malpeli Giorgio, Amato Eliana, Dandrea Mario, Fumagalli Caterina, Debattisti Valentina, Boninsegna Letizia, Pelosi Giuseppe, Falconi Massimo, Scarpa Aldo
Primary Institution: University of Verona
Hypothesis
Is RASSF1A gene silencing by methylation a significant event in pancreatic endocrine tumors?
Conclusion
RASSF1A is always expressed in pancreatic endocrine tumors and its levels are inversely correlated with gene methylation, while RASSF1C is overexpressed in these tumors.
Supporting Evidence
- 80% of pancreatic endocrine tumors showed RASSF1A methylation.
- RASSF1A expression was 6.8 times lower in tumors compared to normal tissues.
- RASSF1C expression was 11.4 times higher in tumors than in normal tissues.
Takeaway
This study looked at how a gene called RASSF1A is turned off in pancreatic tumors and found that while it is usually turned off, it is still present, and another gene, RASSF1C, is turned on a lot in these tumors.
Methodology
The study analyzed the methylation status of RASSF1A in 20 pancreatic endocrine tumors and matched normal pancreas using methylation-specific PCR, quantitative methylation-specific PCR, and pyrosequencing.
Potential Biases
Potential bias may arise from the selection of samples and the methods used for methylation analysis.
Limitations
The study's findings may not apply to all pancreatic endocrine tumors due to the limited sample size and the specific techniques used.
Participant Demographics
The study included 20 patients with pancreatic endocrine tumors, with no specific demographic details provided.
Statistical Information
P-Value
0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website